

Price Sensitive Information

The Meeting of the Board of Directors of Beacon Pharmaceuticals PLC held on 13 November, 2023 at 3.00 PM at its Corporate Office at Beacon Business Centre, 9/B/2, Toyenbee Circular Road, Motijheel C/A, Dhaka-1223 has approved the Un-audited 1st quarterly Financial Statements of the Company for the period ended 30 September, 2023 and has decided, declared and recommended the following price sensitive information accordingly:

The Board of Directors of the Company declared the following financial information:

1) Financial Information:

- a. Earning Per Share (EPS) : Tk. 1.60
b. Net Asset Value Per Share (NAVPS) : Tk. 27.32
c. Net Operating Cash Flow Per Share (NOCFPS) : Tk 0.66

2) Comparative Statement of Financial Information:

Sl. No.	Particulars	30 Sept'23	30 Sept'22
1	Earning Per Share (EPS)	Tk. 1.60	Tk. 0.99
2	Net Asset Value Per Share (NAVPS)	Tk. 27.32	Tk. 26.72
3	Net Operating Cash Flow Per Share (NOCFPS)	Tk. 0.66	Tk. 0.03

Date : 13.11.2023

By order of the Board of Directors

BEACON[®]
Pharmaceuticals PLC
Beacon Business Centre
9/B/2, Toyenbee Circular Road, Motijheel, Dhaka-1223


Khalilur Rahman FCS
Company Secretary

3C X 6 Inch